Evidence map›Paper›PMID 39457532›Full record

ArticleBiomedicines2024

Usage of the Anemia Control Model Is Associated with Reduced Hospitalization Risk in Hemodialysis.

Mario Garbelli, Maria Eva Baro Salvador, Abraham Rincon Bello, Diana Samaniego Toro, Francesco Bellocchio, Luca Fumagalli, Milena Chermisi, Christian Apel, Jovana Petrovic, Dana Kendzia and 8 more

Abstract read
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Mario GarbelliClinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy.
Maria Eva Baro SalvadorNephrocare Spain, Fresenius Medical Care, 08013 Barcelona, Spain.
Abraham Rincon BelloNephrocare Spain, Fresenius Medical Care, 08013 Barcelona, Spain.ORCID 0000-0002-6926-7120
Diana Samaniego ToroNephrocare Spain, Fresenius Medical Care, 08013 Barcelona, Spain.
Francesco BellocchioClinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy.
Luca FumagalliClinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy.
Milena ChermisiClinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy.
Christian ApelHealth Economics and Market Access, Fresenius Medical Care, 61352 Bad Homburg, Germany.
Jovana PetrovicHealth Economics and Market Access, Fresenius Medical Care, 61352 Bad Homburg, Germany.ORCID 0009-0006-1875-1226
Dana KendziaHealth Economics and Market Access, Fresenius Medical Care, 61352 Bad Homburg, Germany.
Jasmine Ion TitapiccoloClinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy.ORCID 0000-0001-5514-8182
Julianna YeungClinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy.
Carlo BarbieriGlobal Digital and Innovation Technology Department, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy.
Flavio MariGlobal Digital and Innovation Technology Department, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy.
Len UsvyatClinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy.
John LarkinClinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy.ORCID 0000-0001-8873-8971
Stefano StuardClinical and Therapeutic Governance EMEA, Medical Affairs, Global Medical Office, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy.ORCID 0000-0002-9546-4507
Luca NeriClinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy.ORCID 0000-0001-5438-1329

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe management of anemia in chronic kidney disease (CKD-An) presents significant challenges for nephrologists due to variable responsiveness to erythropoietin-stimulating agents (ESAs), hemoglobin (Hb) cycling, and multiple clinical factors affecting erythropoiesis. The Anemia Control Model (ACM) is a decision support system designed to personalize anemia treatment, which has shown improvements in achieving Hb targets, reducing ESA doses, and maintaining Hb stability. This study aimed to evaluate the association between ACM-guided anemia management with hospitalizations and survival in a large cohort of hemodialysis patients.

methodsThis multi-center, retrospective cohort study evaluated adult hemodialysis patients within the European Fresenius Medical Care NephroCare network from 2014 to 2019. Patients treated according to ACM recommendations were compared to those from centers without ACM. Data on demographics, comorbidities, and dialysis treatment were used to compute a propensity score estimating the likelihood of receiving ACM-guided care. The primary endpoint was hospitalizations during follow-up; the secondary endpoint was survival. A 1:1 propensity score-matched design was used to minimize confounding bias.

resultsA total of 20,209 eligible patients were considered (reference group: 17,101; ACM adherent group: 3108). Before matching, the mean age was 65.3 ± 14.5 years, with 59.2% men. Propensity score matching resulted in two groups of 1950 patients each. Matched ACM adherent and non-ACM patients showed negligible differences in baseline characteristics. Hospitalization rates were lower in the ACM group both before matching (71.3 vs. 82.6 per 100 person-years,

conclusionsACM-guided anemia management was associated with a significant reduction in hospitalization risk among hemodialysis patients. These results further support the utility of ACM as a decision-support tool enhancing anemia management in clinical practice.

Indexed as

anemia managementArtificial Intelligence (AI)End Stage Renal Disease (ESRD)erythropoiesis-stimulating agent (ESA)personalized medicine

Identifiers

PMID39457532
PMCPMC11504963

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.